Developer Submits BLA for TLX250-CDx Kidney Cancer Imaging in ccRCC
TLX250-CDx elicited a mean sensitivity of 85.5% and a mean specificity of 87.0% in patients with indeterminate renal masses in the phase 3 ZIRCON trial.
TLX250-CDx elicited a mean sensitivity of 85.5% and a mean specificity of 87.0% in patients with indeterminate renal masses in the phase 3 ZIRCON trial.
A stem cell donor changed Laura Tiberi’s life after her leukemia diagnosis. Now she’s sharing hope and inspiration with other transplant recipients.
An abstract is unavailable.
The EMA’s CHMP has recommended the approval of an expanded indication for dostarlimab plus chemotherapy in primary advanced/recurrent endometrial cancer.
Subcutaenous mosunetuzumab plus polatuzumab vedotin demonstrates improved efficacy and response rates compared with rituximab plus polatuzumab vedotin for patients with relapsed/refractory (R/R) LBCL, according to…
Every holiday season, Fox Chase Cancer Center’s Tree of Life Celebration brings together patients, families, donors, researchers, and medical staff to pay tribute to all…
The FDA granted priority review to sunvozertinib for the treatment of advanced NSCLC with EGFR exon 20 mutations, based on promising efficacy and safety data…
BARDA tapped a team of Fred Hutch Cancer Center biostatisticians to determine the biomarkers that will serve as predictors of protective responses in next-generation COVID-19…
Renowned drama school says ‘unprecedented funding challenges’ make degrees unviable from September 2025
In a population-based study of Black women with ovarian cancer, a higher Charlson comorbidity index based on self-reported data and type 2 diabetes were associated…
Consultant Clinical Oncologist NHS advocate and campaigner Politically centre left Wealth inequality creates health inequality